Matthew Norwood is VP of Sales at OBALON THERAPEUTICS INC (OBLN). They have made 1 open-market trade across 1 company since 2016, most recently 2016-10-12.
CIK 0001685642
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $15K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OBLN | 1,000 | $9K |
Shares reported on the most recent Form 4, priced at the 2016-10-12 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OBLN | BUY | 2016-10-12 | 2016-10-12 | $15.00 | $15K | -0.6% | -27.3% | -35.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.